Medical management of unresectable, recurrent low-grade retroperitoneal liposarcoma: Integration of cytotoxic and non-cytotoxic therapies into multimodality care

Surgical Oncology

Volumn 9, Issue 2, 2000, Pages 53-59

  Goss, Geraldine ^a   Demetri, George ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Chemotherapy; Differentiation; Liposarcoma; Retroperitoneum; Troglitazone

Indexed keywords

CIGLITAZONE; CYTOTOXIC AGENT; DACARBAZINE; DOXORUBICIN; EPIRUBICIN; GEMCITABINE; IFOSFAMIDE; MESNA; NAVELBINE; PIOGLITAZONE; ROSIGLITAZONE; TROGLITAZONE;

ADULT; ARTICLE; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER SIZE; CANCER SURVIVAL; CASE REPORT; CLINICAL TRIAL; DISEASE COURSE; HUMAN; LIPOBLASTOMA; LIPOSARCOMA; LUNG METASTASIS; MALE; MULTIMODALITY CANCER THERAPY; POSTOPERATIVE CARE; PRIORITY JOURNAL; QUALITY OF LIFE; RECURRENT CANCER; TUMOR DIFFERENTIATION;

CHROMANS; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; FATAL OUTCOME; HUMANS; LIPOSARCOMA; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RETROPERITONEAL NEOPLASMS; THIAZOLES; THIAZOLIDINEDIONES;

EID: 0033678067     PISSN: 09607404     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-7404(00)00023-2     Document Type: Article

References (26)

1. Sarcomas and other malignancies of soft tissue, retroperitoneum, peritoneum, pleura, heart, mediastinum and spleen
2. Retroperitoneal liposarcoma
3. Influence of biologic factors and anatomic site in completely resected liposarcoma
4. Liposarcoma
5. Outcome and prognosis in retroperitoneal soft tissue sarcoma
6. Prognostic factors predictive of survival for truncal and retroperitoneal soft-tissue sarcoma
7. Retroperitoneal soft-tissue sarcoma: An analysis of 500 patients treated and followed at a single institution
8. Lipomatous tumors
9. Atypical lipoma, atypical intramuscular lipoma, and well differentiated retroperitoneal liposarcoma. A reappraisal of 30 cases formerly classified as well-differentiated liposarcoma
10. Cytogenetic and fluorescence in situ hybridization investigation of ring chromosomes characterizing a specific pathologic subgroup of adipose tissue tumors
11. Correlation between clinicopathological features and karyotype in lipomatous tumors
12. Adjuvant chemotherapy for localised resectable soft tissue sarcoma of adults: Meta-analysis of individual data
13. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: An analysis of 2185 patients treated with anthracycline-containing first-line regimens - A European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study
14. Resectable retroperitoneal soft tissue sarcomas. The effect of extent of resection and postoperative radiation therapy on local tumor control
15. Prognostic factors associated with long-term survival for retroperitoneal sarcoma: Implications for management
16. Dedifferentiated liposarcoma: A clinicopathological analysis of 155 cases with a proposal for an expanded definition of dedifferentiation
17. Well differentiated liposarcoma (atypical lipoma) of deep soft tissue of the extremities, retroperitoneum and miscellaneous sites. A follow up study of 92 cases with analysis of the incidence of 'dedifferentiation'
18. Heterologous elements in the dedifferentiated component of dedifferentiated liposarcoma
19. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans retinoic acid)
20. Convergence of 9-cis retinoic acid and peroxisome proliferator signaling pathways through heterodimer formation of their receptors
21. Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor
22. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ
23. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor γ and the retinoic X receptor
24. Induction of tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma
25. Differentiation of liposarcoma in patients treated with the PPAR-gamma ligand troglitazone: Documentation of biologic activity in myxoid/round cell and pleomorphic subtypes
26. Results of single-agent and combination chemotherapy for advanced soft tissue sarcomas